Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.48 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 5/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | ESRRG | P62508 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23221106 | 0.91 | SLC5A2 (0.46) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 | |
| SCHEMBL9975463 | 0.88 | HSD17B1 (0.51) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 | |
| SCHEMBL9975462 | 0.86 | HSD17B1 (0.46) | HSD17B1HSD17B2SLC5A2SLC5A1APP | |
| SCHEMBL22132986 | 0.86 | SLC5A2 (0.43) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 | |
| SCHEMBL12714458 | 0.86 | SLC5A2 (0.56) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 | |
| SCHEMBL8591760 | 0.83 | SLC5A2 (0.57) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 | |
| SCHEMBL146782 | 0.81 | SLC5A2 (0.41) | SLC5A2ABCB11ADORA3SLC5A1SLC6A4 | |
| SCHEMBL22510538 | 0.81 | SLC5A2 (0.44) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 | |
| SCHEMBL147317 | 0.80 | SLC5A2 (0.46) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 | |
| SCHEMBL27454197 | 0.80 | SLC5A2 (0.43) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885SLC5A2 5/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885SLC5A2 5/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885SLC5A2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.